These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17823358)

  • 1. COPD guidelines: the important thing is not to stop questioning.
    Fabbri LM; Boschetto P; Mapp CE; ;
    Am J Respir Crit Care Med; 2007 Sep; 176(6):527-8. PubMed ID: 17823358
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combined inhaled corticosteroid and long-acting beta-2-agonist in one inhaler in the treatment of chronic obstructive pulmonary disease].
    Pedersen ST
    Ugeskr Laeger; 2005 Jun; 167(23):2504-6. PubMed ID: 16008004
    [No Abstract]   [Full Text] [Related]  

  • 3. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs.
    Suissa S
    Am J Respir Crit Care Med; 2008 Aug; 178(4):322-3. PubMed ID: 18676961
    [No Abstract]   [Full Text] [Related]  

  • 5. [Combination of beta-1 agonist and corticosteroid is advantageous not only in asthma. COPD patients spared exacerbations].
    MMW Fortschr Med; 2002 Oct; 144(44):55. PubMed ID: 12494604
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
    Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov; 145(46):47. PubMed ID: 14699834
    [No Abstract]   [Full Text] [Related]  

  • 8. [Inhalation of beta-2 agonists or corticosteroids as single drugs in comparison with combination therapy of patients with COPD].
    Steurer-Stey C
    Praxis (Bern 1994); 2003 Jul; 92(31-32):1324-5. PubMed ID: 12934343
    [No Abstract]   [Full Text] [Related]  

  • 9. TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease.
    McDonough C; Blanchard AR
    Hosp Pract (1995); 2010 Apr; 38(2):92-3. PubMed ID: 20469618
    [No Abstract]   [Full Text] [Related]  

  • 10. The INSPIRE study: influence of prior use and discontinuation of inhaled corticosteroids.
    Lanes SF; Jara M
    Am J Respir Crit Care Med; 2008 Sep; 178(5):543-4; author reply 544. PubMed ID: 18713851
    [No Abstract]   [Full Text] [Related]  

  • 11. Adherence to inhaled therapy, mortality and hospital admission in COPD.
    Vestbo J; Anderson JA; Calverley PM; Celli B; Ferguson GT; Jenkins C; Knobil K; Willits LR; Yates JC; Jones PW
    Thorax; 2009 Nov; 64(11):939-43. PubMed ID: 19703830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical therapy for COPD: lessons from the real world.
    Calverley PM
    Eur Respir J; 2002 Oct; 20(4):797-8. PubMed ID: 12412666
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Rev Port Pneumol; 2005; 11(6):587-9. PubMed ID: 16514718
    [No Abstract]   [Full Text] [Related]  

  • 15. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
    Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of death in COPD.
    Barnes PJ
    N Engl J Med; 2007 May; 356(21):2211; author reply 2213-4. PubMed ID: 17522406
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of death in COPD.
    Duerden M
    N Engl J Med; 2007 May; 356(21):2212; author reply 2213-4. PubMed ID: 17526087
    [No Abstract]   [Full Text] [Related]  

  • 19. Pre- and post-bronchodilator spirometric values and the degree of reversibility in patients with COPD.
    Lee DK
    Eur Respir J; 2004 Aug; 24(2):332; author reply 332-3. PubMed ID: 15332409
    [No Abstract]   [Full Text] [Related]  

  • 20. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
    Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
    COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.